02566 JIUYUAN GENE
- 6.820
- -0.110-1.59%
JIUYUAN GENE News
The restructuring of the Hong Kong stock market ecosystem is rejuvenating, and next year's IPOs are expected to return to the Global top three.
The Hong Kong Capital Markets are experiencing a strong wave of companies listing in Hong Kong, with many mainland enterprises, from emerging Technology companies like Horizon to industry giants like Midea, SF Express, Heng Rui, Hai Tian, and Mao Ge Ping, turning their attention to Hong Kong.
Honk Kong Market Overview | All three major indices fell, with the Technology Index down over 1%; domestic property stocks and China-Affiliated Brokerage stocks declined, with SenseTime leading the decline in Network Technology stocks, down over 13%; Mao
Network technology stocks generally fell, SenseTime-W dropped 13.51%, Kuaishou-W fell 2.68%; most apple supplier stocks declined, Cowell fell 5.59%, BYD Electronics dropped 3.73%; most biotechnology stocks decreased, Jingtai Holdings-P fell 7.68%, beigene dropped 5.68%;
Hong Kong stocks moving | Jiuyuan Gene (02566) fell over 5% during trading, hitting a new low, down 40% from the offer price, with a total market value of less than 2 billion Hong Kong dollars.
Jiuyuan Genetics (02566) fell over 5% during intraday trading, hitting a low of 7.36 Hong Kong dollars, setting a new record low since its listing, having dropped more than 40% compared to the offering price of 12.42 Hong Kong dollars. As of the time of writing, it is down 4.38%, at 7.42 Hong Kong dollars, with a transaction amount of 14.6585 million Hong Kong dollars and a total market value of less than 2 billion Hong Kong dollars.
[IPO Monthly Report] The Hong Kong stock IPO market remained active in November, with Jinko Electronics' subscription multiple ranking second in Hong Kong history.
Jinwu Finance News | As November approaches, the Hong Kong IPO market continues to remain active, with 7 companies successfully listed on the main board of the exchange this month, covering various industry sectors such as jewelry, biotechnology, and electronic manufacturing. Subscription sentiment this month is high, with a particularly strong demand for Jinko Electronics' shares, followed closely by Jiuyuan Gene. However, the performance on the first day of listing is still similar to last month, with 3 out of 7 new stocks breaking below their issue price and 1 closing flat. On November 26, the second HKEX China Forum will be held in shanghai. The CEO of the Hong Kong Stock Exchange, bonnie chan yi-ting, stated in his speech that they are discussing the inclusion of reits in the Shanghai-Hong Kong Stock Connect with the Shanghai and Shenzhen exchanges.
Express News | Oversubscribed by 826 times! Mao Geping, the "frozen capital king" of Hong Kong IPOs this year.
Insigma Technology's Joint Stock Company Completes Hong Kong Listing
The rumors about artificial "intervention" affecting the multiple on new stock subscriptions are rampant; what is the truth behind Jiu Yuan Gene (02566) experiencing a significant drop on its first day?
Nine-Source Genes fell more than 38% on its first day of listing.
insigma technology (600797.SH): Jointly owned company Jiuyuan Gene was listed on the main board of the Hong Kong Stock Exchange on November 28.
On November 28th, Geelong announced that its wholly-owned subsidiary, Zhejiang Insigma Technology Venture Capital Co., Ltd. (referred to as "Insigma Venture Capital"), a subsidiary of Zhejiang Netxin, will list on the main board of the Hong Kong Stock Exchange on November 28, 2024. The stock code is 2566. This time, Jiu Yuan Genetics, a company invested by Insigma Venture Capital, will globally issue 45,398,800 new shares at an issue price of HK$12.42 per share. After this global offering, the company will hold 24 of its shares through its wholly-owned subsidiary, Insigma Venture Capital.
First day plummet! Alibaba and Fosun buried? 'Weight Loss Miracle Drug' concept stocks debut on the Hong Kong stock market.
On November 28th, Nine Dragons Gene, which embodies the concept of the "miracle weight-loss drug," officially debuted on the Hong Kong stock market, but its performance on the first day was poor, dropping nearly 40% at one point. By the close of trading, Nine Dragons Gene still dropped over 38%.
JiuYuan Gene successfully went public in Hong Kong.
JiuYuan Gene successfully went public in Hong Kong.
New stock debut | Jiuyuan Gene opened lower on the first day, falling 39.61%, with a total market value exceeding 1.8 billion Hong Kong dollars. Huadong Medicine and ali health are cornerstone investors.
Jiyuan Gene is a sino biopharm company that does not engage in genetic engineering business, with over 30 years of experience in the research and development, production, and commercialization of biological pharmaceuticals and medical devices.
Express News | On the first day of listing, the Hong Kong Stock Exchange source gene (02566.HK) opened nearly 40% lower.
Hangzhou Jiuyuan Gene Engineering Raises HK$485 Million From IPO Ahead of Hong Kong Trading Debut
Hangzhou Jinyuan Gene Engineering Shares to Start Trading on Hong Kong Exchange From Nov. 28.
Hangzhou Jinyuan Gene Engineering shares will begin trading on the Hong Kong Exchange from November 28.
Hangzhou Jinyuan Gene Engineering: Final Offer Price HK$12.42
Hangzhou Jinyuan Gene Engineering: Final Offer Price HK$12.42
Futu Daily News | The inflation indicators favored by the Federal Reserve rebound! The attitude towards interest rate cuts in December may be more cautious; the Central Office and the State Office issued the 'Action Plan to Effectively Reduce Logistics Co
The Fed's favorite inflation indicator rebounds! The usa's core PCE price index for October is 2.8% year-on-year; strong consumer spending drives steady growth of 2.8% in the usa's third-quarter GDP; Trump's team is considering digital assets advocate Atkins to serve as SEC chairman.
Selected Announcement | Sino Biopharm's Class 1 innovative drug approved for new indications; LAKAI Pharmaceutical completes the placement of 17.636 million shares, raising approximately 0.23 billion Hong Kong dollars.
The innovative drug GLP-1R/GCGR dual agonist CMS-D005 from cms has received notification of clinical trial approval; Multiple Digital Intelligence is set to launch an IPO from November 28 to December 3, planning to globally issue 25.774 million shares.
Hangzhou Jiuyuan Gene Engineering Is China-Based Biopharmaceutical Company
Hangzhou Jiuyuan Gene Engineering Sets Hong Kong IPO Price at HK$12.42/Share
Chitong Hong Kong Stock Investment Journal | November 28th
Hong Kong Stock Investment Log | November 28, 2024
No Data
